

Ciro Celsa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5106307/publications.pdf>

Version: 2024-02-01

46
papers

874
citations

430874

18
h-index

501196

28
g-index

47
all docs

47
docs citations

47
times ranked

1647
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
2	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
3	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Cut</i> , 2022, 71, 593-604.	12.1	62
4	Diagnostic performance of endoscopic ultrasound through the needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis. <i>Digestive Endoscopy</i> , 2020, 32, 1018-1030.	2.3	49
5	Dynamic angiotensin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 662-673.	5.2	42
6	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.	3.8	41
7	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5613.	4.1	39
8	Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: a systematic review and meta-analysis. <i>Endoscopy</i> , 2021, 53, 1037-1047.	1.8	39
9	Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1061-1072.e8.	4.4	32
10	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	2.5	29
11	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
12	Biliary complications after liver transplantation: current perspectives and future strategies. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 76-92.	1.5	27
13	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. <i>PLoS ONE</i> , 2021, 16, e0245281.	2.5	25
14	Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAteco COVID19 REgistry (SMACORE). <i>Scientific Reports</i> , 2021, 11, 1137.	3.3	22
15	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. <i>Future Oncology</i> , 2019, 15, 3411-3422.	2.4	21
16	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.	2.6	21
17	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	3.7	21
18	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018, 38, 2108-2116.	3.9	20

#	ARTICLE	IF	CITATIONS
19	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	3.7	18
20	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958.	1.0	13
21	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. <i>Liver International</i> , 2021, 41, 1105-1116.	3.9	10
22	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
23	Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. <i>Annals of Hepatology</i> , 2021, , 100568.	1.5	8
24	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7
25	Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study. <i>Endoscopic Ultrasound</i> , 2021, 10, 440.	1.5	7
26	Consequences of Extended Spectrum Beta-lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients. <i>Liver Transplantation</i> , 2021, 27, 43-54.	2.4	5
27	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	3.7	5
28	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
29	Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. <i>Diagnostics</i> , 2022, 12, 1308.	2.6	4
30	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2179-2188.	3.9	3
31	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	1.9	3
32	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> , 0, , .	1.3	3
33	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
34	Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. <i>Gastroenterology Insights</i> , 2022, 13, 117-126.	1.2	3
35	Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1048-1053.	1.0	2
36	Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 237-238.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Editorial: proton pump inhibitor use in cirrhosisâ€”a piece of the puzzle. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 663-664.	3.7	2
38	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
39	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?. <i>Recenti Progressi in Medicina</i> , 2018, 109, 605-608.	0.8	1
40	Systemic therapies for hepatocellular carcinoma: the present and the future. <i>Recenti Progressi in Medicina</i> , 2021, 112, 110-116.	0.8	1
41	Validation and refinement of PROSASH model using the neutrophilâ€”lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020, 1, 6-11.	1.3	0
42	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
43	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
44	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
45	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
46	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022, 12, 1187.	2.6	0